Patent · US Active

RNAi modulation of MLL-AF4 and uses thereof

US8034793B2 · kind B2 · utility

9Cited by

3References

30Claims

0Family size

Assignee

Alnylam Pharmaceuticals, Inc. · US

Inventors

Olaf Heidenreich · Bingen, DE
Hans-Peter Vornlocher · Bayreuth, DE
Philipp Hadwiger · Kulmbach, DE

Key dates

Filing date	Feb 4, 2010
Grant date	Oct 11, 2011
Priority date	—
Expiry date	Feb 4, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/14
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to compositions and methods for modulating the expression of the MLL-AF4 fusion gene, and more particularly to the downregulation of MLL-AF4 by chemically modified oligonucleotides.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.